1. Home
  2. Stocks
  3. Balpharma Share Price

Bal Pharma Share Price

Pharmaceuticals Small Cap

₹123.23 -1.22 (-0.98%)

05 Nov, 2024 17:20

SIP TrendupStart SIP in BALPHARMA

Start SIP
Performance Financial Technical Events FnO Shareholding Pattern More FAQ’s

Performance

  • Low
  • ₹120
  • High
  • ₹128
  • 52 Week Low
  • ₹89
  • 52 Week High
  • ₹158
  • Open Price₹124
  • Previous Close₹124
  • Volume12,692

Investment Returns

  • Over 1 Month -6.19%
  • Over 3 Month + 2.45%
  • Over 6 Month + 22.62%
  • Over 1 Year + 32.79%
SIP Lightning

Smart Investing Starts Here Start SIP with Bal Pharma for Steady Growth!

Bal Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 25.9
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 196
  • P/B Ratio
  • 2.8
  • Average True Range
  • 6.82
  • EPS
  • 6.4
  • Dividend Yield
  • 1
  • MACD Signal
  • -2.64
  • RSI
  • 47.38
  • MFI
  • 30.78

Bal Pharma Financial

IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations73.1394.5881.4992.3070.17
Total Income From Operations73.1394.5881.4992.3070.17
P/L Before Interest, Excpt. Items & Tax5.8110.795.336.055.17
P/L Before Exceptional Items & Tax2.116.671.672.231.53
P/L After Tax from Ordinary Activities1.756.221.261.601.20
Net Profit/Loss For the Period1.756.221.261.601.20
IndicatorMar 24Mar 23
Revenue From Operations [Gross]325.67300.59
Revenue From Operations [Net]325.67300.59
Total Operating Revenues338.54303.10
Total Revenue341.89305.25
Total Expenses329.79296.70
Profit/Loss Before Tax12.118.55
Profit/Loss For The Period10.276.13
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity28.955.07
Net Cash Used In Investing Activity-18.43-22.08
Net Cash Used in Finance Activity-7.7117.43
Net Inc/Dec In Cash And Equivalent2.810.42
Cash And Equivalent End Of Year4.041.23
IndicatorMar 24Mar 23
Total Share Capital15.8015.69
Total Non-Current Liabilities46.5639.52
Total Current Liabilities209.16212.15
Total Capital And Liabilities361.30347.70
Total Non-Current Assets80.1677.75
Total Current Assets281.14269.95
Total Assets361.30347.70
Indicator20242023
EBIT Margin (%)8.076.83
Return On Capital Employed (%)17.9715.27
Return On Equity (%)9.726.37
Long Term Debt To Equity (%)34.4231.78
Book Value/Share (INR)66.8161.21
IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations74.3694.6381.6692.5470.39
Total Income From Operations74.3694.6381.6692.5470.39
P/L Before Interest, Excpt. Items & Tax4.869.894.935.424.07
P/L Before Exceptional Items & Tax0.625.751.271.600.43
P/L After Tax from Ordinary Activities0.265.530.850.970.09
Net Profit/Loss For the Period0.265.530.850.970.09
IndicatorMar 24Mar 23
Revenue From Operations [Gross]326.35304.22
Revenue From Operations [Net]326.35304.22
Total Operating Revenues339.22304.22
Total Revenue342.07305.16
Total Expenses333.02300.41
Profit/Loss Before Tax9.054.75
Profit/Loss For The Period7.452.62
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity22.81-1.84
Net Cash Used In Investing Activity-18.89-22.18
Net Cash Used in Finance Activity-1.2124.40
Net Inc/Dec In Cash And Equivalent2.710.37
Cash And Equivalent End Of Year4.201.49
IndicatorMar 24Mar 23
Total Share Capital15.8015.69
Total Non-Current Liabilities47.2240.14
Total Current Liabilities203.04209.33
Total Capital And Liabilities319.53313.17
Total Non-Current Assets85.3885.02
Total Current Assets234.15228.16
Total Assets319.53313.17
Indicator20242023
EBIT Margin (%)7.165.56
Return On Capital Employed (%)20.8616.30
Return On Equity (%)10.664.03
Long Term Debt To Equity (%)52.4547.85
Book Value/Share (INR)43.8240.60

Bal Pharma Technicals

EMA & SMA

Current Price
₹123.23
-1.22 (-0.98%)
pointer
  • stock-down_img
  • Bullish Moving Average 7
  • stock-up_img
  • Bearish Moving Average 9
  • 20 Day
  • ₹125.27
  • 50 Day
  • ₹127.22
  • 100 Day
  • ₹124.38
  • 200 Day
  • ₹117.88

Resistance and Support

124.52 Pivot Speed
  • R3 134.83
  • R2 131.42
  • R1 127.93
  • S1 121.03
  • S2 117.62
  • S3 114.13

Is Bal Pharma Worth Buying?

BUY SELL HOLD

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Bal Pharma has an operating revenue of Rs. 343.19 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 3% needs improvement, ROE of 10% is good. The company has a debt to equity of 52%, which is bit higher. The stock from a technical standpoint is trading below to its 50DMA and around 6% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 21% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 79 which is a FAIR score but needs to improve its earnings, a RS Rating of 52 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 35 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation. (+)

Bal Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-08-12 Quarterly Results, ESOP & A.G.M.
2024-05-28 Audited Results & Final Dividend
2024-02-12 Quarterly Results
2023-11-08 Quarterly Results & ESOP
2023-08-11 Quarterly Results & A.G.M.

Bal Pharma F&O

Bal Pharma Shareholding Pattern

50.86%
0.13%
33.15%
15.86%
  • NSE Symbol
  • BALPHARMA
  • BSE Symbol
  • 524824
  • Managing Director
  • Mr. Shailesh D Siroya
  • ISIN
  • INE083D01012

Bal Pharma FAQs

Bal Pharma share price is ₹123 As on 05 November, 2024 | 17:06

The Market Cap of Bal Pharma is ₹196.2 Cr As on 05 November, 2024 | 17:06

The P/E ratio of Bal Pharma is 25.9 As on 05 November, 2024 | 17:06

The PB ratio of Bal Pharma is 2.8 As on 05 November, 2024 | 17:06

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

The Vigilance Awareness Week for the year 2024 (VAW 2024) would be observed from October 28, 2024 to November 03, 2024
“सत्यनिष्ठा की संस्कृनि सेराष्र की समद्ृधि” “Culture of Integrity for Nation's Prosperity”
e-pledge link (https://pledge.cvc.nic.in/)

5paisa Capital Ltd. CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

*Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

Contact Us

Attention Investors

  • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
  • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
  • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

Email: support@5paisa.com

Support Desk Helpline: 8976689766

©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.